ArticlePilot and feasibility studies2017

Evaluation of neurological changes in secondary progressive multiple sclerosis patients treated with immune modulator MIS416: results from a feasibility study.

Gill A Webster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.